A systematic follow-up protocol achieving a low hemodialysis graft thrombosis rate.


Journal

The journal of vascular access
ISSN: 1724-6032
Titre abrégé: J Vasc Access
Pays: United States
ID NLM: 100940729

Informations de publication

Date de publication:
Nov 2019
Historique:
pubmed: 20 4 2019
medline: 25 2 2020
entrez: 20 4 2019
Statut: ppublish

Résumé

Graft is an alternative to native arteriovenous fistula to ensure permanent vascular access in hemodialysis patients. The most common complication is significant stenosis, which frequently causes thrombosis and graft loss. Periodic monitoring and surveillance with elective correction of stenotic lesions can prolong graft survival. To describe the effect of early diagnosis of significant stenosis on the rate of thrombosis and graft patency. Retrospective, observational study of a cohort of 86 prevalent patients undergoing hemodialysis with a graft as their vascular access. We applied a systematic follow-up protocol of 115 grafts based on various screening methods of monitoring (clinical monitoring, pre-pump arterial pressure, dynamic venous pressure, percentage of recirculation, and dose of dialysis) in conjunction with surveillance (normalized intra-access venous pressure and access flow). The annual rates of thrombosis, and primary, primary-assisted, and secondary patency were assessed. The incidence of significant stenosis and thrombosis was 57.4% (65/115) and 39.0% (45/115), respectively. Of all screening procedures, normalized intra-access venous pressure was the best predictor of significant stenosis (hazards ratio, 7.71; 95% confidence interval, 3.06-19.46). The annual rate of thrombosis fluctuated from 0 to 0.26 thromboses/patient/year, with an average rate of 0.14 thromboses/patient/year. Primary, primary-assisted, and secondary patency were 74%/79%/82%, 50%/60%/66%, and 23%/35%/37% at 1, 2, and 5 years, respectively. The implementation of a systematic graft follow-up protocol combined with monitoring and surveillance enabled early diagnosis and elective correction of significant stenosis, prolonged graft patency, and a low thrombosis rate.

Identifiants

pubmed: 31002279
doi: 10.1177/1129729819838795
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

683-690

Auteurs

Pilar Caro Acevedo (P)

Department of Nephrology, Hospital Ruber Juan Bravo, Madrid, Spain.

Rosa Marchante (R)

Department of Nephrology, Hospital Ruber Juan Bravo, Madrid, Spain.

Israel J Thuissard (IJ)

School of Doctoral Studies and Research, Universidad Europea, Madrid, Spain.

David Sanz-Rosa (D)

School of Doctoral Studies and Research, Universidad Europea, Madrid, Spain.

Raquel Amann (R)

Department of Nephrology, Hospital Ruber Juan Bravo, Madrid, Spain.

Beatriz Hernandez (B)

Department of Nephrology, Hospital Ruber Juan Bravo, Madrid, Spain.

Ramón Delgado (R)

Department of Nephrology, Hospital Ruber Juan Bravo, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH